Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma Authors: Zhou Lu, Huanchen Shi, Rongshan Gao, Chengjie zhong, Wei Zhang, Jian Zhu, Jianhang Huang, Ronghua Liu, Yun Xing, Yiwei Chu, Haixiang Sun, Guoming Shi, Aiwu Ke, Jian Zhou, Jiabin Cai, Jia Fan, Pingting Gao, Cheng Huang Published: 2025 ABSTRACT AbstractParaoxonase-1 (PON1) is specifically expressed in the liver and has crucial effects on various liver diseases. The functions and underlying mechanisms of PON1 in hepatocellular carcinoma (HCC) remain unclear. Here, we demonstrate that PON1 serves as a metabolic regulator to counteract regulatory T (Treg) cell-mediated immunosuppression, thereby suppressing HCC progression. Mechanistically, PON1 promotes Von Hippel-Lindau protein (VHL)-mediated ubiquitination and degradation of hypoxia-inducible factor alpha (HIF-1α), leading to attenuated lactic acid production and limited Treg cell accumulation in the HCC microenvironment. In clinical settings, higher PON1 expression is correlated with a better prognosis in patients with HCC. Recombinant PON1 protein (rPON1) effectively impeded tumor growth. Furthermore, enhancing Pon1 expression with quercetin sensitized HCC to anti-programmed death-1(PD-1) therapy in murine HCC. Our findings elucidate a role of PON1 in orchestrating lactic acid production to relieve immunosuppression and suppress HCC, paving the way for targeting PON1 as a therapeutic strategy.Subject terms: Tumour immunology, Cancer metabolism Introduction Hepatocellular carcinoma (HCC) is the fourth most commonly diagnosed cancer and the third deadliest malignancy globally1,2. Despite advances in surgical techniques and clinical implementation of targeted therapies and immunotherapies, only a minority of patients with HCC achieve durable clinical benefit3,4. Substantial therapeutic challenges persist. Therefore, uncovering the underlying molecular mechanisms to identify promising therapeutic targets is of great significance for improving the survival of patients with HCC. Paraoxonase-1 (PON1) is a glycoprotein that is mainly expressed in the liver and secreted into the bloodstream, where it binds to high-density lipoprotein (HDL)5. PON1 exhibits multiple enzymatic activities, including aryl esterase, paraoxonase and lactonase activities6. Due to its antioxidant and anti-inflammatory properties, PON1 is involved in a variety of liver diseases, such as chronic hepatitis, alcoholic liver cirrhosis, non-alcoholic steatohepatitis (NASH), and HCC7,8. Patients with chronic liver diseases show decreased PON1 activity, and low PON1 levels are inversely correlated with the severity of alcoholic hepatitis9. Elevated PON1 expression plays a protective role against NASH through antioxidation10,11. PON1 expression is downregulated in patients with HCC12. Our previous research identified serum PON1 as a diagnostic biomarker for microvascular invasion in HCC13,14. In addition, PON1 has been predicted to be a tumor biomarker with significant implications for prognosis, targeted therapy, and immunotherapy of patients with HCC through bioinformatics analysis15,16. Thus, the role of PON1 in HCC has gained more and more attention in recent years. However, from a mechanistic point of view, the impact of PON1 on HCC development and immunotherapy is still poorly understood. Harnessing the immune system against HCC has been identified as an effective therapeutic strategy17,18. However, the efficacy of immunotherapies is limited by the immunosuppressive nature of the tumor microenvironment (TME)19,20. Accumulating evidence indicates that aberrant metabolic reprogramming, a hallmark of cancer, is the culprit in the formation of immunosuppressive microenvironments21,22. Lactate was reported to regulate tumor-associated macrophage (TAMs) signaling and gene expression to directly promote tumor development23. Meanwhile, tumor cell-derived succinate can activate the succinate receptor SUCNR1 to trigger pro-tumorigenic TAM polarization24. In addition, triacylglycerol biogenesis was demonstrated to promote the immunosuppressive functions of TAMs25. Taurocholic acid contributes to lung metastasis of colorectal cancer by triggering the accumulation of myeloid-derived suppressor cells26. Our previous study revealed that leucine-induced regulatory LARS B cells contribute to colorectal cancer immunoevasion27. Regulatory T (Treg) cells, characterized by the expression of the master transcription factor forkhead box protein p3 (FOXP3), are key regulators of tumor-associated immunosuppression. Single-cell analysis of tumor-infiltrating lymphocytes (TILs) confirmed an increase in Treg cells in HCC28. Different metabolic programs, including glycolysis, oxidative phosphorylation, fatty acid oxidation, fatty acid synthesis, and amino acid metabolism, along with their essential regulators, modulate Treg cell proliferation, migration, and function29–31. Hence, elucidating the metabolic mechanisms that lead to the accumulation of Treg cells in HCC is crucial to reverse immunosuppression and develop more efficacious immunotherapies. In this study, we found that PON1 was downregulated during HCC progression and low PON1 expression was associated with poor prognosis. In mouse models of HCC, overexpression of Pon1 in tumor cells inhibited tumor growth in a Treg-dependent manner. Mechanistically, we deciphered that PON1 decreased lactic acid production in the TME via Von Hippel-Lindau protein (VHL)-mediated ubiquitination of hypoxia-inducible factor alpha (HIF-1α), thereby reducing Treg cell infiltration in HCC. Furthermore, upregulation of Pon1 levels by quercetin sensitized HCC to anti-programmed death-1 (PD-1) therapy in mice. Collectively, our findings reveal that PON1 acts as a metabolic regulator to suppress HCC progression by alleviating Treg-driven immunosuppression, suggesting that enhancing PON1 expression may be a promising adjuvant immunotherapy strategy for HCC. Results PON1 Suppresses HCC growth and is Associated with Better Prognosis PON1 was specifically expressed in the liver of both mice and humans (Supplementary Fig. 1a–b). Analyses of The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases revealed that PON1 transcript levels were significantly downregulated in HCC (Supplementary Fig. 1c and Fig. 1a). Similarly, microarray data from the Gene Expression Omnibus (GEO) database showed that PON1 was reduced in HCC (Fig. 1b). Immunohistochemical analysis of PON1 expression in 10 paired HCC and adjacent non-tumor tissues (Cohort 1, Table S1) showed significantly reduced protein levels in tumor tissues compared to those in peritumoral tissues (Fig. 1c). Analysis of TCGA data via the University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN) revealed that PON1 transcript levels were negatively correlated with tumor grade and stage (Fig. 1d). Additionally, receiver operating characteristic (ROC) analysis indicated that PON1 levels were significantly accurate in predicting HCC prognosis (area under the curve, AUC = 0.759, Supplementary Fig. 1d). According to the Kaplan-Meier survival analysis, patients with HCC with high PON1 expression had significantly improved overall survival and progression-free survival prognosis in The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort (Supplementary Fig. 1e and Fig. 1e). To further address the prognostic value of PON1 in HCC, we analyzed PON1 expression in 100 human HCC specimens (Cohort 2, Table S2). Consistently, higher PON1 expression predicted better prognosis in patients with HCC (Fig. 1f). To investigate the role of PON1 in HCC progression, we constructed stable Pon1-overexpressing (Pon1-OV) and -knockdown (Pon1-KD) Hepa1-6 cells via lentiviral transduction and then established mouse models of HCC (Fig. 1g, h). The growth of Pon1-OV orthotopic and subcutaneous tumors was hindered compared to that of the controls (Pon1-NC), while the growth of Pon1-KD subcutaneous tumors was faster than that of the controls (Pon1-NC) (Fig. 1i–k). We also confirmed the anti-tumor effects of PON1 in Hep-53.4 cells (Supplementary Fig. 1f). Additionally, we generated Pon1 gene-deficient (Pon1-KO) mice and induced HCC using two distinct methods: orthotopic inoculation of Hepa1-6 cells and hydrodynamic tail vein injection of oncogenic plasmids (pT3-myr-AKT-HA: pT/Caggs-NRASV12: pCMV(CAT)T7-SB100 = 1:1:0.04), as previously described32 (Supplementary Fig. 1g). Notably, Pon1 deficiency markedly accelerated tumor progression in both models compared to that in wild-type (WT) controls (Supplementary Fig. 1h, i). These findings suggest that PON1 is not only a prognostic biomarker but also has a tumor suppressive role in HCC. Overexpression of PON1 suppresses HCC progression. a PON1 expression in normal tissues (N, n = 150) from the GTEx and TCGA databases was compared with that in tumor tissues of HCC (T, n = 371) from the TCGA database. b PON1 expression was analyzed in normal tissues (N) and HCC tumor tissues (T) using datasets from the GEO database. The analysis included the following datasets: GSE14520 (225 T, 220 N), GSE76427 (115 T, 52 N), GSE138178 (49 T, 49 N), GSE105130 (25 T, 25 N), and GSE104310 (12 T, 8 N). c PON1 protein expression was analyzed in paired adjacent non-tumor (NT, n = 10) and HCC tumor (T, n = 10) tissues from 10 patients. d Correlations of PON1 expression with the tumor stage and tumor grade of HCC in the TCGA database. Sample sizes for each group are indicated within the figure. e Analysis of overall and progression-free survival of patients in the TCGA dataset. Sample sizes for each group are indicated within the figure. f Kaplan-Meier survival analysis of 100 patients with HCC, stratified by high (n = 50) or low (n = 50) PON1 expression. g, h Pon1 mRNA levels in Hepa1-6 cells by qRT–PCR (n = 3 independent experiments). Representative western blot of PON1 protein expression in Hepa1-6 cells. The samples derive from the same experiment but different gels for PON1 and another for ACTIN were processed in parallel. The data are representative of two independent experiments. i Representative liver images of C57BL/6 mice orthotopically injected with Pon1-NC or Pon1-OV Hepa1-6 cells (n = 3 mice per group). j Representative images of subcutaneous tumors from Pon1-OV and Pon1-NC groups. Tumor weight and volume were quantified for each group (n = 10 mice per group). k Representative images of subcutaneous tumors from Pon1-KD and Pon1-NC groups. Tumor weight and volume were quantified for each group (n = 10 mice per group). In the box plots, the center line represents the median, the bounds of the box indicate the IQR, and the whiskers extend to 1.5 × IQR. Data are presented as median with IQR (a, b, d) and as mean ± SEM (g, h, j, k). Statistical significance was determined by two-tailed unpaired Student’s t-test (a, b, c, g, h, j, k), Kruskal–Wallis test with Dunn’s post hoc comparison (d), or log-rank test (e, f). TCGA-LIHC The Cancer Genome Atlas Liver Hepatocellular Carcinoma, GTEx Genotype-Tissue Expression, GSE Gene Expression Omnibus Series, N normal tissues, T tumor tissues, H histochemistry, NT non-tumor tissues, TPM transcripts per million, NC negative control, OV overexpression, KD knockdown. Source data are provided as a Source Data file. Treg cell Reduction is Essential for PON1-Mediated Suppression of HCC Progression We found that Pon1 overexpression did not affect the proliferation of Hepa1-6 cells in vitro (Supplementary Fig. 1j, k). Notably, in immunodeficient Rag-1-/- mice, subcutaneous tumors generated from Pon1-OV and Pon1-NC Hepa1-6 cells showed indistinguishable progression (Supplementary Fig. 1l), suggesting that PON1-mediated tumor suppression was fundamentally dependent on immunomodulation. To explore the potential function of PON1 in anti-tumor immune responses, we performed Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) analysis on HCC samples. As shown in Fig. 2a, Treg cells were significantly reduced in PON1high HCC tumors according to the TCGA-LIHC cohort. Subsequently, we conducted an examination of immune cell populations in patients with HCC (Supplementary Fig. 2a). Twenty HCC tissues from Zhongshan Hospital were categorized into high- and low-PON1 expression groups based on their PON1 expression levels (Cohort 3, Table S3). Notably, the frequency of Treg cells was higher in the PON1-low expression group than in the PON1-high expression group, whereas other immune cell subsets showed no significant alterations (Fig. 2b). Furthermore, a negative correlation pattern was observed between PON1 expression and the proportion of Treg cells (Fig. 2c and Supplementary Fig. 2b). Next, we deciphered the immune atlas of Pon1-NC and Pon1-OV subcutaneous tumors (Supplementary Fig. 2c). Compared with the Pon1-NC group, the Pon1-OV group displayed a decrease in Treg cells, accompanied by an enhanced anti-tumor response of CD8+ T cells (Fig. 2d, e). Meanwhile, the Pon1-KD group exhibited considerably higher Treg cell infiltration and a lower anti-tumor response of CD8+ T cells than the Pon1-NC group (Fig. 2f, g). The trend in Treg cell changes was consistent between the orthotopic and subcutaneous tumor models. Specifically, Treg cells were reduced in the Pon1-OV group compared to those in the control group (Supplementary Fig. 2d). Conversely, in orthotopic grafts or spontaneous tumors, the proportion of Treg cells was higher in Pon1-KO mice than in WT mice (Supplementary Fig. 2e, f). Our data suggest that changes in PON1 expression mainly affect the proportion of Treg cells and anti-tumor response of CD8+ T cells in HCC. PON1 exerts an anti-tumor effect in HCC by reducing the infiltration of Treg cells. a Characteristics of immune cell composition in HCC from the TCGA dataset, stratified by PON1 mRNA expression and analyzed by CIBERSORT (High, n = 40; Low, n = 40) and ssGSEA (High, n = 93; Low, n = 93). b Based on PON1 mRNA expression levels, 20 HCC tissues were categorized into PON1high (n = 10 patients) and PON1low (n = 10 patients) groups (left). The proportion of tumor-infiltrating immune cells in each group was detected via spectral flow cytometry (right). c Correlation analysis between PON1 expression and the proportion of Treg cells (n = 20 patients). d Treg cell percentages and e expression of IFN-γ, TNF-α, PD-1, Lag3, and Tim3 in tumor-infiltrating CD8+ T cells, measured in Pon1-NC and Pon1-OV groups (n = 4 mice per group). f Treg cell percentage and g expression of IFN-γ, TNF-α, PD-1, Lag3, and Tim3 in tumor-infiltrating CD8+ T cells, measured in Pon1-NC and Pon1-KD groups (n = 4 mice per group). h Schematic representation of the coculture model of Hepa1-6 cells and CD4+ T cells (Hepa1-6: CD4+ T = 1:100). i CD4⁺ T cell differentiation into Tregs was assessed after coculture with Hepa1-6 cells subjected to Pon1 overexpression or its paired control (n = 5 independent experiments). A parallel assessment was performed with cells subjected to Pon1 knockdown or its paired control (n = 4 independent experiments). j Mice were treated with anti-CD25 antibody (αCD25, 1.5 mg/kg/time), followed by subcutaneous injection of Hepa1-6 cells with different treatments. k Representative images of subcutaneous tumors are shown, along with measurements of tumor weights and growth curves for Pon1-NC and Pon1-OV groups, with or without αCD25 treatment (n = 4 mice per group). l Representative images of subcutaneous tumors are shown, along with measurements of tumor weights and growth curves for Pon1-NC and Pon1-KD groups, with or without αCD25 treatment (n = 5 mice per group). In the box plots, the center line represents the median, the box boundaries indicate the IQR, and the whiskers extend to 1.5 × IQR. Data are presented as median with IQR (a) and as mean ± SEM (b, d–g, i, k, l). Statistical significance was determined by two-tailed unpaired Student’s t-test (a, b, d–g, i) and Pearson correlation analysis (c). In panels k and l, tumor growth over time was analyzed by two-way ANOVA with Sidak’s multiple comparisons test, while final tumor weights were compared by one-way ANOVA with Holm-Sidak’s multiple comparisons test. NK natural killer cell, NKT natural killer T cell, DC dendritic cell, Treg regulatory T cell, NC negative control, OV overexpression, KD knockdown, FCM flow cytometry, ns not significant. Schematic diagrams (h, j) were created with BioRender. Lu, Z. (2025) https://BioRender.com/qjx1ksf. Source data are provided as a Source Data file. We then investigated the effects of PON1 on CD8+ T cells and Treg cells in vitro. CD8+ T cells co-cultured with Pon1-NC or Pon1-OV Hepa1-6 cells exhibited comparable anti-tumor activity (Supplementary Fig. 2g, h). However, the results of co-culture experiments showed that overexpression of Pon1 in Hepa1-6 cells impaired the ability of CD4+ T cells to differentiate into Tregs, whereas down-regulation of Pon1 expression in Hepa1-6 cells promoted Treg cell differentiation (Fig. 2h, i). More importantly, by depleting Tregs with anti-CD25 antibodies (αCD25, Supplementary Fig. 2i), we demonstrated that Treg cell ablation abrogated the anti-tumor effect mediated by Pon1 overexpression and reversed the pro-tumor effect induced by Pon1 knockdown (Fig. 2j–l). Collectively, our results establish that PON1 exerts anti-tumor effects in a Treg-dependent manner. Lactic acid is a key metabolic player in PON1-regulated treg cell Infiltration Given that PON1 is a liver-specific gene, we next sought to identify the key player involved in PON1-mediated crosstalk between tumor cells and Tregs. Quantitative proteomics using data-independent acquisition (DIA) was applied to Pon1-NC and Pon1-OV Hepa1-6 cells. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the differentially expressed proteins revealed considerable enrichment in metabolic pathways (Fig. 3a). Gene set enrichment analysis (GSEA) also showed that the genes associated with glycolysis, citric acid cycle, carbon metabolism, and amino acid synthesis were reduced in Pon1-OV subcutaneous tumors (Fig. 3b and Supplementary Fig. 3a). To identify the key metabolites regulated by PON1, we performed targeted metabolomics on Pon1-NC and Pon1-OV subcutaneous tumors and identified 36 metabolites that showed significant differences between the two groups (Fig. 3c and Supplementary Fig. 3b, c). Of note, organic acid levels were significantly reduced in Pon1-OV tumors (Fig. 3d). Detailed analysis of the organic acids with significant differences showed that the lactic acid content was the highest, and its level was lower in the Pon1-OV group than in the Pon1-NC group (Fig. 3e, f). We subsequently measured lactic acid production in the subcutaneous tumors using a lactic acid test kit. As expected, Pon1 overexpression reduced lactic acid accumulation, whereas Pon1 knockdown had the opposite effect (Fig. 3g). These results suggest that PON1 acts as a metabolic regulator of lactic acid generation in HCC cells. PON1 impairs lactic acid generation in HCC cells. a KEGG pathway analysis of differential proteins between Pon1-NC and Pon1-OV Hepa1-6 cells. b Enriched metabolic pathways identified via GSEA using differentially expressed genes (DEGs) in Pon1-NC and Pon1-OV subcutaneous tumors. c Metabolomic analysis of Pon1-NC and Pon1-OV subcutaneous tumors via PLS-DA. d Relative abundance of each metabolite class in the different groups (n = 4 mice per group). e Heatmap showing changes in metabolites between Pon1-NC Pon1-OV subcutaneous tumors. f Concentrations of differential organic acids (n = 4 mice per group). g Lactic acid levels in subcutaneous tumor tissue were measured using a lactic acid assay kit. Levels were compared between the Pon1-OV group and its paired control group (n = 6 mice per group), and between the Pon1-KD group and its paired control group (n = 4 mice per group). h Correlation analysis of PON1 expression, lactic acid content, and Treg cell proportion (n = 20 patients). i ECAR was measured in Hepa1-6 cells subjected to different treatments (n = 3 independent experiments). j Foxp3 expression in CD4+ T cells treated with different doses of lactic acid (n = 4 independent experiments). k Proportion of Treg cells treated with lactic acid or MCT1 inhibitor (Azd3965,1 μM) (n = 5 independent experiments). l Schematic diagram of mice injected with Pon1-NC or Pon1-OV Hepa1-6 cells and treated with PBS or lactic acid. m Representative images of subcutaneous tumors are shown, along with the tumor weights and volumes from the different groups (n = 8 mice per group). n Lactic acid content (n = 4 mice per group) and Treg cell percentages (n = 10 mice per group) were measured in subcutaneous tumors from the different groups. Data are presented as mean ± SEM (f,g,i–k,m,n). Statistical significance was determined by permutation test (b), two-tailed unpaired Student’s t-test (f,g,i), Pearson correlation analysis (h), one-way ANOVA with Dunnett’s test (j), or one-way ANOVA with Holm-Sidak’s multiple comparisons test (k,m,n). For (d), either the unpaired t-test or the Wilcoxon Rank-Sum Test test was selected based on the results of normality and equal variance tests. NES normalized enrichment score, FDR false discovery rate, PLS-DA partial least squares discriminant analysis, vs. versus, NC negative control, OV overexpression, KD knockdown, ECAR extracellular acidification rate, Treg regulatory T cell, PBS phosphate-buffered saline, LA lactic acid. Schematic diagram i was created with BioRender. Lu, Z. (2025) https://BioRender.com/qjx1ksf. Source data are provided as a Source Data file. Interestingly, in patients with HCC, PON1 expression was negatively correlated with lactic acid levels, whereas lactic acid levels were positively correlated with the Treg cell proportion (Fig. 3h and Table S2). Complementary in vitro and in vivo experimental models were used to investigate the role of lactic acid in PON1-mediated Treg cell infiltration. We first measured the glycolytic function in Pon1-OV and Pon1-KD Hepa1-6 cells in vitro. The reduced extracellular acidification rate (ECAR) in Pon1-OV cells and elevated ECAR in Pon1-KD cells relative to controls implied that PON1 modulated glycolytic function (Fig. 3i). In vitro co-culture experiments demonstrated that lactate dehydrogenase A (Ldha) knockdown in Hepa1-6 cells significantly inhibited Treg cell generation compared to that in the control group (Supplementary Fig. 3d). In vitro, we induced Treg cell differentiation using TGF-β. Lactic acid directly promoted Treg cell differentiation, as reported previously33, and inhibition of lactic acid transport via the monocarboxylate transporter 1 (MCT1) inhibitor Azd3965 reversed this effect (Fig. 3j, k). In addition, equivalent lactic acid concentrations (5 mM) had no effect on Treg cell proliferation or migration but slightly reduced Treg cell death (Supplementary Fig. 3e–g). Tan et al. reported that the expanded Treg population in tumors consists not of thymus-derived Tregs (tTregs) but of peripherally induced Tregs (pTregs), which are predominantly derived from T helper 1 (Th1) cells34. Single-cell sequencing revealed the selective expansion of pTregs over tTregs in Pon1-KD Hepa1-6 subcutaneous tumors relative to Pon1-NC controls (Supplementary Fig. 3h, i). Consistent with established findings, enriched pTregs displayed heightened Th1-specific molecules, and pseudotemporal trajectory reconstruction further indicated their probable developmental origin from Th1 cells (Supplementary Fig. 3j, k). These results demonstrate that lactic acid-driven Treg cell differentiation constitutes the principal mechanism underlying enhanced Treg cell infiltration. Recombinant PON1 protein (rPON1) did not affect Treg cell differentiation, ruling out a direct role for PON1 in Treg cell infiltration (Supplementary Fig. 3l, m). In vivo, intratumoral lactic acid injection promoted HCC tumor growth accompanied by increased Treg cell infiltration (Supplementary Fig. 3n, o). More importantly, lactic acid abrogated the tumor-suppressive function of PON1 in HCC by promoting Treg cell infiltration (Fig. 3l–n). Collectively, these data prove that lactic acid is a metabolic messenger for PON1-mediated crosstalk between tumor cells and Treg cells. PON1 Disrupts Lactic acid Production via VHL-mediated HIF-1α Ubiquitination Next, we aimed to delineate the molecular mechanism underlying the regulation of lactic acid production by PON1. Subcellular fractionation and confocal microscopy showed that PON1 was predominantly localized in the cytoplasm (Fig. 4a, b). Meanwhile, subcellular localization analysis of differentially expressed proteins between the Pon1-NC and Pon1-OV groups identified the cytoplasm as the predominant compartment (Fig. 4c). Further analysis revealed that HIF-1α, the master transcription factor controlling lactic acid production, is a potential target of PON1 (Fig. 4d). The protein level of HIF-1α in Hepa1-6 cells was attenuated upon Pon1 overexpression, while elevated upon Pon1 knockdown (Fig. 4e). However, changes in Pon1 expression had no effect on Hif-1α mRNA expression (Fig. 4f). Consistently, the protein level of HIF-1α in Pon1-OV subcutaneous tumors was decreased but increased in Pon1-KD tumors relative to control tumors (Fig. 4g, h). There was no significant difference in Hif-1α mRNA expression among Pon1-OV, Pon1-KD, and the control tumors (Fig. 4i, j). The above results suggest that PON1 regulates HIF-1α protein levels without affecting its mRNA expression. Given that ubiquitination is a major modification regulating HIF-1α protein degradation, we tested whether PON1 affects the ubiquitination of HIF-1α. Ubiquitination assay of HIF-1α in Pon1-overexpressing or Pon1-knockdown Hepa1-6 cells treated with the proteasome inhibitor MG132 showed that Pon1 overexpression increased the ubiquitination of HIF-1α, whereas Pon1 knockdown suppressed HIF-1α ubiquitination under hypoxia conditions (Fig. 4k). These results demonstrate that PON1 impairs lactic acid production by promoting HIF-1α protein ubiquitination in HCC cells. PON1 promotes HIF-1α protein degradation in HCC cells. a Western blot analysis of PON1 expression in cytosolic and nuclear fractions of Hepa1-6 cells. The samples derive from the same experiment but different gels for Tubulin, Histone 3, and another for PON1 were processed in parallel. b Confocal images showing the co-localization between PON1 (green) and the endoplasmic reticulum (ER)-Tracker Red (red) in Hepa1-6 cells. Scale bar: 5 μm. c Proteome-wide subcellular distribution in Pon1-NC and Pon1-OV Hepa1-6 cells. d Volcano plot depicting differential proteins in Pon1-NC and Pon1-OV Hepa1-6 cells (n = 3 biologically independent replicates per group). e HIF-1α protein levels in Hepa1-6 cells following Pon1 overexpression or knockdown. f Hif-1α transcript levels were compared between the Pon1-OV group and its paired control (n = 5 independent experiments), and between the Pon1-KD group and its paired control (n = 4 independent experiments). g, h PON1 and HIF-1α protein levels were measured in subcutaneous tumors (n = 3 mice per group). The samples derive from the same experiment but different gels for HIF-1α, another for PON1 and another for ACTIN were processed in parallel. i, j Pon1 and Hif-1α transcript levels were measured in subcutaneous tumors from the different groups (n = 4 mice per group). k Ubiquitination levels of HIF-1α in Hepa1-6 cells with Pon1 overexpression or knockdown. The Input samples derive from the same experiment but different gels for HIF-1α, another for PON1 and another for ACTIN were processed in parallel. The IP samples derive from the same experiment but different gels for HIF-1α and another for Ub. Data are presented as mean ± SEM f, i, j. Statistical significance was determined by an empirical Bayes method with Benjamini-Hochberg correction (d) and by a two-tailed unpaired Student’s t-test f,i,j. Data in (a, b, e, k) are representative of two independent experiments. WLC whole cell lysate, ER endoplasmic reticulum, FC fold change, NC negative control, OV overexpression, KD knockdown, IP Immunoprecipitation, ns not significant, Ub ubiquitination. Source data are provided as a Source Data file. VHL has been reported to govern the degradation of HIF-1α protein35. Immunofluorescence assays revealed co-localization of PON1, VHL, and HIF-1α in Hepa1-6 cells (Fig. 5a). Subsequently, we co-transfected Flag-tagged Hif-1α plasmids and Vhl plasmids into Pon1-overexpressing Hepa1-6 cells using Lipofectamine 2000. After 48 h, protein interactions were analyzed using co-immunoprecipitation (co-IP). As shown in Supplementary Fig. 4a, there were pairwise interactions among PON1, VHL, and HIF-1α. Additionally, co-IP assays directly performed in Hepa1-6 cells revealed endogenous interactions among HIF-1α, VHL, and PON1 (Fig. 5b). Glutathione S-transferase pull-down (GST pull-down) assay confirmed the direct interaction between PON1 and VHL (Supplementary Fig. 4b). These data indicate that PON1 promotes HIF-1α ubiquitination and degradation by recruiting VHL to bind HIF-1α (Fig. 5c). Next, we investigated the role of VHL in PON1-mediated anti-tumor effects. Using lentiviral transduction, we first generated Vhl-knockdown (Vhl-KD) and dual-modified (Vhl-KD+Pon1-OV) Hepa1-6 cells, and subsequently established mouse subcutaneous xenograft tumor models with these cells (Supplementary Fig. S4c). As shown in Supplementary Fig. 4d, e, Vhl knockdown promoted lactic acid production by suppressing HIF-1α ubiquitination. However, Pon1 overexpression failed to reverse either the accumulated HIF-1α or the increase in lactic acid secretion caused by Vhl knockdown (Supplementary Fig. 4d, e). Consistent with these predictions, the Vhl-KD group exhibited significantly enhanced Treg cell infiltration and increased tumor volume compared with the control group (Supplementary Fig. 4f, g). Notably, Pon1 overexpression in the Vhl-KD background (Vhl-KD- Pon1-OV) did not affect Treg cell infiltration or tumor growth compared with Vhl-KD alone (Supplementary Fig. 4f, g). Interestingly, Vhl knockdown did not affect PON1 secretion or activity (lactonase function), while Pon1 overexpression elevated these parameters (Supplementary Fig. 4h). This establishes that PON1’s tumor-suppressive function requires direct binding to VHL and operates independent of both its secretion and catalytic activity. Moreover, administration of LW6, which degrades HIF-1α through the VHL-dependent proteasome pathway, reversed the tumor growth induced by Pon1 knockdown (Fig. 5d). This reversal coincided with reduced lactic acid production and Treg cell infiltration (Fig. 5e, f). Together, these results demonstrate that PON1 regulates Treg-mediated immunosuppression in HCC through the VHL-HIF-1α-lactic acid signaling axis. PON1 binds to VHL directly. a Confocal images showing the co-localization between PON1 (green), VHL (red), and HIF-1α (yellow) in Hepa1-6 cells. Scale bar: 5 μm. b Co-IP of endogenously expressed PON1, VHL, and HIF-1α in Hepa1-6 cells exposed to hypoxia. The samples derive from the same experiment but different gels for PON1, VHL, and another for HIF-1α were processed in parallel. c Schematic diagram of PON1 interaction with VHL and HIF-1α. d Schematic diagram of mice injected with Pon1-NC or Pon1-KD Hepa1-6 cells and followed by administration of DMSO or LW6. Representative images of subcutaneous tumors are shown, along with the tumor weights and volumes from the different groups (n = 4 mice per group). e, f Lactic acid levels and Treg cell percentages in subcutaneous tumors from the different groups (n = 4 mice per group). Data are presented as mean ± SEM d–f. Statistical significance was determined by one-way ANOVA with Holm‑Sidak’s multiple comparisons test d–f. Data in (a, b) are representative of two independent experiments. IP immunoprecipitation, Ub ubiquitination, NC negative control, KD knockdown, Treg regulatory T cell. Schematic diagram d was created with BioRender. Lu, Z. (2025) https://BioRender.com/qjx1ksf. Source data are provided as a Source Data file. Enhancing PON1 levels is a Promising immunotherapy strategy for HCC To further evaluate the potential clinical value of PON1 in HCC progression, we treated tumor-bearing mice with rPON1 (Fig. 6a). As expected, rPON1 dramatically suppressed tumor growth, accompanied by a decrease in lactic acid levels and Treg cell proportions (Fig. 6a–c). rPON1 did not affect the proliferation of Hepa1-6 cells (Supplementary Fig. 5a). Additionally, in mice depleted of Tregs using anti-CD25 antibodies, the antitumor effects of rPON1 were abrogated (Supplementary Fig. 5b). Certain drugs, dietary factors, and lifestyle factors were reported to stimulate Pon1 transcription activation36–39. We treated Hepa1-6 cells with stimulants, which have been documented to change Pon1 expression. The results showed that quercetin upregulated Pon1 mRNA expression in a dose-dependent manner (Fig. 6d). To explore the mechanism of quercetin-induced Pon1 upregulation, we analyzed Pon1-regulating transcription factors (PPARγ, JUN, NF-κB, SP1, SREBP2, and AHR) in Hepa1-6 cells exposed to 10 μM quercetin36–39. Quercetin significantly upregulated expression of Pparg and Jun (Supplementary Fig. 5c). Dual-luciferase reporter assays demonstrated that expression plasmids for both Jun and Pparg activated Pon1 transcription (Supplementary Fig. 5d, e). Critically, however, only the PPARγ antagonist T0070907 abolished quercetin-induced Pon1 upregulation (Supplementary Fig. 5d–f). We then evaluated the efficacy of quercetin monotherapy and its synergistic combination with anti-PD-1 therapy in HCC. Inhibition of tumor growth, a decrease in lactic acid levels, and a lower percentage of Treg cells were observed in tumors following quercetin administration (Fig. 6e–g). Quercetin inhibited Hepa1-6 cell proliferation at high concentrations in vitro (Supplementary Fig. 5g). Moreover, the anti-tumor effects of quercetin were abolished in mice with depleted Treg cells (Supplementary Fig. 5h). Surprisingly, combination therapy involving anti-PD-1 and quercetin resulted in a substantial delay in tumor growth compared to that in the monotherapy groups (Fig. 6e). These results demonstrate that quercetin inhibits HCC growth and act synergistically with immune checkpoint blockade (ICB) in our models. This suggests that elevating PON1 levels represents a promising therapeutic strategy for HCC. Increasing PON1 levels blunts tumor growth and synergizes with anti-PD-1 blockade. a Schematic diagram of tumor bearing-mice treated with IgG or rPON1. Representative images, tumor weights, and growth curves of Hepa1-6 tumors from mice intraperitoneally injected with IgG or rPON1 (n = 4 mice per group). b, c Lactic acid levels and Treg cell percentages in subcutaneous tumors from the different groups (n = 4 mice per group). d Pon1 mRNA expression was measured in Hepa1-6 cells treated with quercetin, simvastatin, pitavastatin (n = 4 independent experiments) or with atorvastatin (n = 3 independent experiments). e Schematic diagram of tumor bearing-mice treated with IgG, anti-PD-1, quercetin, or anti-PD-1 combined with quercetin. Representative images of subcutaneous tumors are shown, along with measurements of tumor weight and growth curves for each group (n = 4 mice per group). f, g Lactic acid levels and Treg cell percentages in subcutaneous tumors from the different groups (n = 4 mice per group). Data are presented as mean ± SEM. Statistical significance was determined by two-tailed unpaired Student’s t-test (b, c), one-way ANOVA with Dunnett’s test (d), and one-way ANOVA with Holm-Sidak’s multiple comparisons test (f, g). In panel a, tumor growth over time was analyzed by two-way ANOVA with Sidak’s multiple comparisons test, and final tumor weights were compared by two-tailed unpaired Student’s t-test. In panel e, tumor growth over time was analyzed by two-way ANOVA with Sidak’s multiple comparisons test, and final tumor weights were compared by one-way ANOVA with Holm-Sidak’s multiple comparisons test. rPON1 recombinant PON1 protein, Ab antibody, NC negative control, Treg regulatory T cell, ns not significant. Schematic diagrams (a, e) were created with BioRender. Lu, Z. (2025) https://BioRender.com/qjx1ksf. Source data are provided as a Source Data file. Discussion In recent years, the predictive and prognostic significance of PON1 in HCC has attracted much attention. However, the role and mechanism of PON1 in HCC development remained elusive. In this study, we found that PON1 was not only a predictor of HCC but also a suppressor of HCC progression. We proved the protective role of PON1 in HCC and revealed the underlying immunometabolic mechanisms (Fig. 7). Briefly, PON1 was downregulated during HCC development, and low PON1 expression was correlated with a poor prognosis. Additionally, PON1 inhibited HCC growth by decreasing lactic acid-driven Treg cell infiltration. Mechanistically, PON1 impaired lactic acid generation by recruiting VHL to degrade the HIF-1α protein. Moreover, enhanced PON1 expression overcame Treg-mediated immunosuppression in tumors, thereby improving HCC responsiveness to immunotherapy. Our results demonstrate the protective role of PON1 in HCC and suggest that PON1 is a promising therapeutic target for HCC. A model illustrating the immunometabolic role of PON1 in HCC pathogenesis. As shown, liver specific PON1 mediates the crosstalk between tumor cells and immune cells. Decreased PON1 expression in tumors increases lactic acid production, which in turn acts as a signaling mediator to promote Treg infiltration and foster an immunosuppressive tumor microenvironment conducive to growth. Ub ubiquitination, Treg regulatory T cell. Schematic diagram was created with BioRender. Lu, Z. (2025) https://BioRender.com/eepitq7. Based on proteomic analysis, metabolic pathways were the most significantly altered functional category upon PON1 modulation. Targeted metabolomics revealed that lactic acid was a key driver of Treg cell infiltration. Lactic acid regulates both tumor cells and multiple immune cell types, including CD4+ and CD8+ T cells, as established in prior studies30,40. We demonstrated that PON1-mediated tumor suppression was fundamentally dependent on immunomodulation (Supplementary Fig. 1j–l). Although CD8+ T cell function was enhanced in vivo in Pon1-OV tumors, in vitro co-culture experiments revealed that Pon1-OV Hepa1-6 cells suppressed Treg cell generation compared to Pon1-NC controls, without significantly affecting CD8+ T cell function (Fig. 2i and Supplementary Fig. 2g, h). Given that Pon1 overexpression affects multiple metabolic pathways, compensatory mechanisms are likely to regulate CD8+ T cells in this setting, which could explain the absence of functional modulation in vitro (Fig. 3a). In vivo intratumoral lactic acid injection significantly enhanced Treg cell infiltration (Supplementary Fig. 3o). Crucially, Treg depletion experiments in both the Pon1-KD and Pon1-OV models established the Treg-dependent nature of PON1-mediated anti-tumor effects (Fig. 2k, l). Collectively, these data identify the PON1-lactic acid-Tregs axis as a pivotal regulatory mechanism in HCC, with in vivo CD8+ T cell functional alterations predominantly attributable to Treg cell reduction. PON1 has been reported to be critical for maintaining normal physiological levels of crucial lipid metabolic intermediates. PON1 deficiency significantly reduces circulating glycerol and β-hydroxybutyrate, while enhancing macrophage cholesterol synthesis41. Although PON1 has been implicated in glucose homeostasis and glycolytic regulation, its mechanistic basis remains elusive42. Here, we demonstrated that Pon1 overexpression reprograms tumor metabolism, suppresses multiple intermediates, and mechanistically delineated its role in lactic acid biogenesis. These findings provide insights into PON1’s function as an important metabolic regulator. In this study, we demonstrated that PON1 suppressed lactic acid production primarily by recruiting VHL to degrade HIF-1α. Although PON1 is a secretory protein with multiple enzymatic activities, we found that its anti-tumor function is independent of these properties. VHL binding did not affect PON1 secretion or lactonase activity (Supplementary Fig. 4h). Moreover, Pon1 overexpression in Vhl-KD cells increased both its secretion and enzymatic activity (Supplementary Fig. 4h), but it failed to suppress tumor growth in the absence of VHL (Supplementary Fig. 4g). Collectively, these results indicate that the anti-tumor function of PON1 depends on VHL and is independent of its secretory properties and intrinsic enzymatic activity. Although PON1’s well-established antioxidant activity, which involves hydrolyzing lipid peroxides, protects against various diseases such as cardiovascular and chronic liver disease5,11,43,44, we found that modulating PON1 expression did not alter intracellular reactive oxygen species (ROS) levels in vitro (Supplementary Fig. 6a, b). This suggests that its mechanism in HCC is distinct from its classical antioxidant role. Furthermore, while the diagnostic significance of PON1 fucosylation has been established in cancers including HCC45–47, and our previous study identified serum PON1 as a robust biomarker of microvascular invasion13,14, the functional role of PON1 fucosylation in hepatocarcinogenesis remains unclear. Elucidating this represents a mechanistically significant research direction that warrants future investigation. To investigate the therapeutic potential of PON1, we generated rPON1. Treatment with rPON1 recapitulated the anti-tumor efficacy of Pon1 overexpression, significantly suppressing tumor growth, reducing lactic acid production, and decreasing Treg cell infiltration in murine models. While hepatic secretion of PON1 into circulation requires HDL for enzymatic stabilization and antioxidant functionality6, our data demonstrate that PON1-mediated tumor suppression operates independently of enzymatic activity (Supplementary Fig. 4g, h). PON1 exerts its anti-tumor effect through VHL interaction. The role of HDL in this process remains incompletely characterized. Critically, whether exogenous rPON1 associates with HDL in vivo and how this interaction modulates rPON1’s enzymatic activity constitute key determinants for clinical translation, warranting further investigation. PON1 is downregulated in multiple pathological conditions. Certain drugs, dietary components, and lifestyle interventions have been found to positively modulate PON1 activity and expression36–39. We found that quercetin upregulates Pon1 expression by activating PPARγ (Supplementary Fig. 5f). Although the therapeutic potential of quercetin in HCC has been previously documented48, we establish its ability to suppress HCC progression through a metabolic-immune regulatory axis. Furthermore, the combination of quercetin and an anti-PD-1 blockade synergistically inhibited HCC progression compared to single-agent treatments in murine HCC. These findings suggest that PON1 is a promising therapeutic target and reveal mechanisms for quercetin-immunotherapy combinations in HCC. In summary, our study reveals a previously unrecognized metabolic function of PON1 in alleviating immunosuppression. PON1 reduces Treg cell infiltration in HCC by destroying lactic acid production, thereby suppressing tumor growth. We also elucidate the mechanism of the PON1-VHL-HIF-1α axis in lactic acid production in murine HCC cell lines and mouse models. However, given the constraints of our models, the function of the PON1-VHL-HIF-1α axis in human HCC warrants further validation through clinically relevant humanized platforms, notably dual-humanized patient-derived xenograft models and patient-derived organoids. Based on the data presented here, we suggest that increasing PON1 levels can abolish lactic acid-induced immunosuppression, which is a potentially effective therapeutic option for HCC and one of the most favored strategies for ICB combination therapy. Methods Clinical specimens Ten formalin-fixed, paraffin-embedded HCC tissues (10 tumor tissues and 10 adjacent non-tumor tissues) from 10 patients utilized for PON1 detection were obtained from Zhongshan Hospital, Fudan University (Cohort 1, Table S1). HCC tissue microarrays were obtained from 100 patients with HCC who underwent successful surgical resection in 2008. All patients were followed-up until August 2014. Detailed clinical and pathological information for the patients is presented in Table S2 (Cohort 2). Fresh tumor tissues from twenty patients with HCC who underwent surgery at Zhongshan Hospital, Fudan University, were collected to detect PON1 expression, lactic acid levels, and Treg cell ratios (Cohort 3, Table S3). The samples were obtained with informed consent. Mice C57BL/6 mice were purchased from GemPharmatech Co., Ltd. (Nanjing, China). Pon1-knockout (Pon1-KO) mice on a C57BL/6 background were generated and provided by Cyagen Biosciences (Guangzhou, China). Rag-1-/-mice were provided by Prof. Yiwei Chu. All mice were male, 6- to 8-week-old, and in a specific pathogen-free condition, temperature- and humidity-controlled vivarium with a 12 h light/dark cycle at the Fudan University animal facility (Shanghai, China). Sex was not considered in the study. The PCR primers for genotyping are listed in Table S4. Cell lines Hepa1-6 cell line was purchased from the National Collection of Authenticated Cell Cultures (Shanghai, China). Hep-53.4 cell line was purchased from EFE Biotechnology Co., Ltd (Shanghai, China). Cells were cultured in Dulbecco’s Modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) at 37 °C in a humidified atmosphere with 5% CO2. Hypoxia conditions (1% O2) were induced using a tri-gas incubator (5% CO2/balance N2). All cells were authenticated by short tandem repeat profiling and showed no mycoplasma contamination. Plasmids, lentiviral construction, and cell transfection The Hif-1α plasmid carrying a Flag tag and the Vhl plasmid without a tag were purchased from Hanyin Biotechnology (Shanghai, China). Plasmids were transfected into Hepa1-6 cells using Lipofectamine 2000 reagent for co-IP assays. Lentiviral vectors for Pon1 overexpression, as well as for Pon1 and Vhl gene silencing (using shRNAs), were purchased from GeneChem (Shanghai, China). Cells were cultured in 6 cm dishes at a density of 1 × 105 cells for 24 h. The lentivirus was diluted in medium containing HitransG infection enhancer (GeneChem, Shanghai, China) and added to the cells. After overnight incubation, the supernatant was replaced with fresh medium, and the cells were cultured for an additional 48 h. To select for stably-transfected cells, puromycin (Beyotime, ST551) was added to the culture medium at a concentration of 5 μg/mL. The plasmids pT3-myr-AKT-HA, pT/Caggs-NRASV12, and pCMV (CAT) T7-SB100 were purchased from Ke lei Biological Technology Co., Ltd (Shanghai, China). Mouse subcutaneous tumor model C57BL/6 mice were randomly assigned to experimental groups. During the inoculation procedure, mice were briefly restrained, and the hair on the right dorsal side was shaved and disinfected with 70% ethanol. Using a 1 mL syringe, a single-cell suspension (200 µL) containing either 8 × 10⁶ Hepa1-6 cells or 5 × 10⁶ Hep-53.4 cells was subcutaneously injected into the right dorsal region of each mouse. Based on established literature using our cell line and our preliminary tumor growth curve experiments, the mouse subcutaneous tumors were harvested at the 14-day endpoint49,50. This time point was selected because the tumor volume remains below 1500 mm³ and is optimal for assessing the immune microenvironment. Orthotopic HCC mouse model C57BL/6 mice were anesthetized by intraperitoneal injection of 2% pentobarbital. The mice were placed in a supine position, and a 1 cm longitudinal incision was made in the upper abdominal region to expose the largest liver lobe. A suspension containing 2 × 10⁶ Hepa1-6 cells in 20 μL of phosphate-buffered saline (PBS) was slowly injected into the liver parenchyma using a sterile 30-gauge removable needle attached to a 50-μL Hamilton microsyringe (Hamilton Company, Reno, Nevada, USA). After injection, the needle was held in place for 30 seconds to prevent leakage. The abdominal wall and skin were then sutured layer by layer. All animals were euthanized 14 days post-inoculation as reported50. Livers were harvested and photographed. Hydrodynamic tail vein injection model of HCC An HCC model was established in C57BL/6 mice by hydrodynamic injection of a plasmid mixture (20 µg pT3-myr-AKT-HA, 20 µg pT/Caggs-NRASV12, and 0.8 µg pCMV(CAT) T7-SB100 in 2.0 mL saline) into the tail vein over 5–7 s. At the four-week time point indicated by the survival data, the mice were euthanized, and their livers were collected, weighed, and photographed. Targeted metabolomics Pon1-NC and Pon1-OV tumors were freeze-dried in liquid nitrogen. Metabolomic analysis was performed by Metabo-Profile (Shanghai, China) using a Q300 kit51. Briefly, samples were homogenized in water with zirconium oxide beads and extracted in cold methanol containing internal standards. After centrifugation, the supernatant was derivatized for 60 min at 30 °C using a Biomek 4000 workstation (Beckman Coulter, Pasadena, CA, USA). The derivatized samples were diluted with 50% methanol, centrifuged again, and then subjected to LC-MS analysis. Quantification was carried out using a UPLC-MS/MS system (ACQUITY UPLC-Xevo TQ-S, Waters, Millford, Massachusetts, USA) with external calibration standards. Raw data were processed using TMBQ software (v1.0, Human Metabolomics Institute) for peak integration and quantification. Statistical analysis was performed with iMAP v1.0 (Metabo-Profile). Strict quality control procedures were implemented throughout the entire process. Proteomic analysis by Data-Independent Acquisition Mass Spectrometry Pon1-NC and Pon1-OV Hepa1-6 cells were trypsin-digested and analyzed using data-independent acquisition (DIA) mass spectrometry (Bioprofile, Shanghai, China). LC-MS/MS was performed on an Orbitrap Astral mass spectrometer coupled to a Vanquish Neo UHPLC system (Thermo Fisher Scientific, Waltham, MA, USA). Peptides were separated on a 50 cm µPAC™ Neo column at 2.2 μL/min using a gradient of 0.1% formic acid in water (A) and 0.1% formic acid in 80% acetonitrile (B) over 8 min. The gradient increased from 4 to 99% B. Full MS scans (380–980 m/z) were acquired at a resolution of 240,000 with 5 ms injection time. DIA-MS/MS scans (150–2000 m/z) used 2 m/z isolation windows, 3 ms injection time, and 25 NCE. Data were processed with DIA-NN (v1.8) against the UniProtKB/Swiss-Prot mouse database (2024-03-25 release). Ubiquitination analysis The impact of PON1 on HIF-1α stability in Hepa1-6 cells was examined via ubiquitination assays. Briefly, cells from different groups were cultured under hypoxic conditions for 24 h and treated with MG132 (10 μM) for 4 h prior to collection. The ubiquitination level of HIF-1α was determined by immunoprecipitation with anti-HIF-1α antibody, followed by western blotting using anti-Ub antibody. All antibodies used in this study are listed in Table S5. In vitro co-culture assay between tumor cells and CD4+ T cells 48-well plates were coated overnight at 4 °C with anti-CD3 antibody (2 μg/mL). Total CD4+ T cells were isolated from C57BL/6 mouse spleens using the EasySep™ Mouse CD4+ T Cell Isolation Kit (STEMCELL, 19852). Purified CD4+ T cells (5 × 10⁵ cells/well) were co-cultured with differentially treated Hepa1-6 cells at a 100:1 ratio in anti-CD3-precoated wells, supplemented with soluble anti-CD28 antibody (2 μg/mL) in RPMI-1640 medium supplemented with 10% FBS. After 48 h incubation under standard conditions (37 °C, 5% CO₂), FOXP3 expression in CD4+ T was analyzed via flow cytometry. In Vitro Treg cell differentiation assay 48-well plates were coated overnight at 4 °C with anti-CD3 antibody (2 μg/mL). Total CD4+ T cells were isolated from C57BL/6 mouse spleens using the EasySep™ Mouse CD4+ T Cell Isolation Kit (STEMCELL, 19852). The purified CD4+ T cells (5 × 10⁵ per well) were seeded into the pre-coated plates and stimulated with soluble anti-CD28 antibody (2 μg/mL) and TGF-β (1 ng/mL) in the presence of varying concentrations of lactic acid. Cells were harvested at 48 or 72 h for analysis of FOXP3 expression. Immunofluorescence staining and observation A total of 1 × 10⁴ Pon1-OV Hepa1-6 cells were seeded in a confocal-specific dish. When the cells reached ~50% confluency, they were prepared for staining. The culture medium was aspirated, and 1–2 mL of PBS was added to gently wash the cells 1–2 times. After completely removing the PBS, pre-warmed (37 °C) ER-Tracker Red (Beyotime, C1041S) staining working solution was added to the dish and incubated with the cells at 37 °C for 15–30 min. The ER-Tracker Red staining working solution was then removed, and the cells were stained with DAPI (Beyotime, C1002) for 5 min, followed by 1–2 washes with PBS. Images were acquired on a Leica TCS SP5 confocal microscope (Leica Microsystems Wetzlar GmbH, Wetzlar, Germany) using 405, 488, and 594 nm lasers. All images were processed using LAS X Life Science Microscope Software, where individual color channels were merged. Flow cytometry Cells isolated from human and mouse tissues were incubated with an anti-mouse CD16/32 antibody on ice for 15 min to block Fc receptor-mediated nonspecific binding. The cells were then stained with cell surface markers. After 30 min surface antibody incubation at 4 °C, cells were washed twice. Intracellular molecular staining was performed using the FOXP3 Fix/Perm Buffer (Biolegend, 421401) according to the manufacturer’s protocol. For cytokine detection, cells were stimulated in vitro with cell stimulation cocktail (containing phorbol myristate acetate, ionomycin, monensin, and brefeldin A) for 5 h, then fixed, permeabilized, and stained with the indicated antibodies. Fluorescence was measured using a BD FACSCelesta™ flow cytometer (Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA), and data were analyzed using FlowJo software (Tree Star, Ashland, USA). All antibodies used in the present study are listed in Table S6. Co-immunoprecipitation Cells were lysed using cell lysis buffer (Beyotime, P0013) supplemented with protease inhibitors. For immunoprecipitation, the lysates were incubated overnight at 4 °C with specific primary antibodies (PON1, Abcam, ab126597, 1:100; HIF-1α, AiFang, AF02369, 1:50; VHL, Santa Cruz, sc-514041, 1:50). Protein A/G agarose beads (Roche, 11243233001) were then added, and the incubation continued for an additional 4 hours at 4 °C. The beads were collected and washed three times with radioimmunoprecipitation assay (RIPA) buffer (Beyotime, P0013B). Both whole cell lysates (input) and immunoprecipitates were analyzed by western blotting. All antibodies used in this study are listed in Table S5. Western blotting Total proteins were extracted in RIPA buffer (Beyotime, P0013B), supplemented with protease inhibitors and then centrifuged in a microcentrifuge at 12,000 g for 15 min at 4 °C to collect the supernatant. The total protein concentrations in the supernatants were quantified using bicinchoninic acid assay (Beyotime, P0009). Proteins were separated via sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). Then, membranes were blocked for 1 h with 5% nonfat dry milk and incubated with the various primary antibodies overnight at 4 °C. Subsequently, the membranes were incubated with the secondary antibodies. Protein bands were detected using an enhanced chemiluminescence detection reagent (YEASEN, 36208ES60). All antibodies used in this study are listed in Table S5. RNA extraction, Quantitative Real-Time PCR, and RNA-sequencing analysis Total RNA was extracted using an RNAsimple Total RNA Kit (TIANGEN, DP419). The cDNA was generated using the Hifair® II 1st Strand cDNA Synthesis SuperMix for qPCR (gDNA digester plus) kit (YEASEN, 11119ES60) and then amplified with Hieff UNICON qPCR SYBR Green Master Mix (YEASEN, 11200ES). Quantitative Real-time PCR (qRT-PCR) detection was performed using an ABI 7500 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). The primer sequences are listed in Table S4. For high-throughput RNA sequencing (RNA-seq), total RNA was extracted from the tumors using the TRNzol universal reagent (TIANGEN, DP424). Library construction and sequencing were performed by NovelBio Bio-Pharm Technology (Shanghai, China). Seahorse assay The ECAR in Hepa1-6 cells with Pon1 overexpression or knockdown was measured using an XFe96 Extracellular Flux Analyzer (Agilent Technologies, Santa Clara, CA, USA) and Seahorse XF Cell Glycolysis Stress Test Kit (Agilent, 103020-100), according to the manufacturer’s protocols. Following equilibration, the assay was performed using a drug injection regimen that included 0.5 μM rotenone/antimycin A and 50 mM 2-deoxyglucose. Measurement of lactic acid production Lactic acid levels in tumor tissues were measured using an L-lactic acid assay kit (Nanjing Jiancheng Bioengineering Institute, A019-2-1). Briefly, for lactic acid detection, the samples, enzyme working solution, and chromogen were added in steps and incubated at 37 °C for 10 min. The absorbance was measured at 530 nm using a TECAN SPARK 10 M Microplate Reader. A standard curve was used to determine lactic acid concentrations in the samples. Bioinformatic analyses The mRNA expression data and clinicopathological data for LIHC were downloaded from the TCGA database. GTEx data for normal liver tissues were downloaded from the GTEx website. Gene expression microarray datasets for HCC tissues and adjacent normal liver tissues were searched and downloaded from the GEO database (GSE14520, GSE76427, GSE138178, GSE105130, and GSE104310). The relationship between PON1 expression and tumor grade and tumor stages was analyzed using the UALCAN web portal based on TCGA data. KEGG pathway enrichment analysis was performed on the differentially expressed genes. GSEA was performed on the RNA-seq-derived differentially expressed genes using GSEA software (v3.0) with default parameters. Principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and orthogonal PLS-DA were performed to examine intrinsic clusters in the metabolomic data. Statistical analyses No statistical method was used to predetermine sample size. Instead, sample sizes were chosen based on established practices in cell biological and animal experimentation. No data points were excluded from the analyses. Blinding was not implemented during outcome assessment. Statistical analyses were performed by GraphPad Prism 8.0 and R (v4.3.1). Comparisons between two groups were performed using a two-tailed unpaired Student’s t-test. For comparisons among three or more groups, one of the following tests was applied as appropriate, including one-way ANOVA with Holm-Sidak’s multiple comparisons test, one-way ANOVA with Dunnett’s test, Kruskal–Wallis test with Dunn’s post hoc comparison, or two-way ANOVA with Sidak’s multiple comparisons test. Survival curves were generated using the Kaplan–Meier method and compared with the log-rank test. Correlations were assessed using the Pearson correlation coefficient. Data are presented either as median with interquartile range (IQR) or as mean ± standard error of the mean (SEM), as indicated in the figure legends. All p values are indicated in the figures. Schematic diagrams were created using BioRender.com under publication license. Ethics statement The study involving human samples was approved by the Institutional Review Board of Zhongshan Hospital, Fudan University (Ethical number: B2021-081). All animal experiments were approved by the Animal Welfare and Ethics Subcommittee of the Department of Laboratory Animal Science, Fudan University (Ethical number: 202309031S). Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Supplementary information Reporting Summary Peer Review File Source data Source data Acknowledgements This work was supported by grants from the National Natural Science Foundation of China (NSFC) (81572298,81871929, and 82072667 to C.H.; 82272703, 82473201 to J.C.), the Special Research Fund for Liver Cancer Diagnosis and Treatment from the China Anti-Cancer Association (H2020-044 to C.H), the Chinese Society of Clinical Oncology (CSCO) Cancer Research Fund (H2023-150 to C.H.), the Shanghai Health Young Talents (2022YQ068 to Z.L.), the National Science and Technology Major Project of China (2023YFA1800204 to R.L.), the Science and Technology Plan Project of Xiamen (3502Z20224012), and the Shanghai Municipal Health Commission Collaborative Innovation Cluster Project (2024CXJQ02). We gratefully acknowledge Prof. Xiaojing Gan’s research group (School of Basic Medical Sciences, Fudan University) for their guidance and assistance with the GST-pull-down experiments. We are also grateful to Prof. Yiwei Chu for providing the Rag-1-/- mice. We thank the Core Facility of Shanghai Medical College, Fudan University, for their technical support with flow cytometry. We thank Metabo-Profile and Bioprofile for their technical assistance in metabolomic and proteomic sequencing analyses. Author contributions C.H., Z.L., and P.G. conceived and supervised the study. Z.L., H.S.¹, and R.G. designed and performed most experiments, and drafted the manuscript with input from C.H. and P.G. W.Z. and H.S.² maintained mouse colonies; J.Z. measured lactic acid levels. Y.X. carried out flow cytometry under the supervision of R.L. and Y.C. C.Z., A.K., and J.C. collected clinical samples under the guidance of G.S., J.Z., and J.F. J.H. and H.S.¹ performed bioinformatic analyses using TCGA-HCC and RNA-seq data. Peer review Peer review information Nature Communications thanks Ajithkumar Vasanthakumar, Mark Borris Aldonza and the other anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available. Data availability The mass spectrometry proteomics data have been deposited with the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD060315. RNA-seq data generated in this study are available in the NCBI Sequence Read Archive under BioProject accession PRJNA1203080. Metabolomics data have been deposited in the Metabolights under the accession number MTBLS12950. The single-cell RNA-seq data generated by mice in this study are available in the NCBI Sequence Read Archive under BioProject accession PRJNA1322306. Source data are provided with this paper. Code availability All the custom scripts developed for this study have been made openly accessible and can be found on the GitHub repository at https://github.com/williams062/code. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Zhou Lu, Huanchen Shi, Rongshan Gao. Contributor Information Zhou Lu, Email: lu.zhou1@zs-hospital.sh.cn. Pingting Gao, Email: gao.pingting@zs-hospital.sh.cn. Cheng Huang, Email: huang.cheng@zs-hospital.sh.cn. Supplementary information The online version contains supplementary material available at 10.1038/s41467-025-66168-y. References Associated Data Supplementary Materials Supplementary information Reporting Summary Peer Review File Source data Data Availability Statement The mass spectrometry proteomics data have been deposited with the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD060315. RNA-seq data generated in this study are available in the NCBI Sequence Read Archive under BioProject accession PRJNA1203080. Metabolomics data have been deposited in the Metabolights under the accession number MTBLS12950. The single-cell RNA-seq data generated by mice in this study are available in the NCBI Sequence Read Archive under BioProject accession PRJNA1322306. Source data are provided with this paper. All the custom scripts developed for this study have been made openly accessible and can be found on the GitHub repository at https://github.com/williams062/code.